Glenmark gets USFDA’s tentative approval for Dimethyl Fumarate Delayed-Release Capsules

09 Oct 2019 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Dimethyl Fumarate Delayed?Release Capsules, 120 mg and 240 mg, a generic version of Tecfidera Capsules, 120 mg and 240 mg, of Biogen Inc.  

According to IQVIA sales data for the 12 month period ending August 2019, the Tecfidera Capsules, 120 mg and 240 mg market achieved annual sales of approximately $3.7 billion.  Glenmark’s current portfolio consists of 161 products authorized for distribution in the US marketplace and 49 ANDA’s pending approval with the USFDA.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2000.60 -10.90 (-0.54%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×